Epilepsy and orphan drug development: an interview with Ana Mingorance

Written by Ana Mingorance (Loulou Foundation, London, UK)

In this Expert Perspective from the Video Journal of Biomedicine, Ana Mingorance (Loulou Foundation, London, UK) speaks about the current status of drug development for epilepsy. Ana also describes how the landscape of this field has changed, with new developments in technology as well as challenges associated with the regulatory approval of new drugs leading to a shift in focus to developing novel drugs to treat orphan epilepsy indications. 

About Ana Mingorance: 

Ana Mingorance is a neuroscientist specialized in drug discovery for rare epilepsy syndromes. She is the Chief Development Officer of the Loulou Foundation and an independent consultant helping companies and patient organizations develop new medicines for developmental and epileptic encephalopathies.

About the Video Journal of Biomedicine

The Video Journal of Biomedicine is a platform for authors to discuss their recently published, peer-reviewed paper, published in a Future Science Group journal or elsewhere, in a short, high-quality, interview-style video. Each video provides the opportunity for authors to personally discuss their latest published work in more detail; highlighting its importance to the field, placing it in context, and discussing future implications. The aim is for the readers to gain a comprehensive understanding of the publication. Find out more at: www.biomedicine.video

You might also like: